Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales

Madrigal Pharmaceuticals (MDGL) was on investors’ radar on Thursday, after the company reported encouraging real-world data for Rezdiffra, its lead drug for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can lead to scarring, liver failure, and cancer.Across f…